Role of mitogen-activated protein kinase (MAPK) in troglitazone-induced osteoblastic cell death

Toxicology

Volumn 234, Issue 1-2, 2007, Pages 73-82

  Jung, Ju Young ^a   Yoo, Chong Il ^a   Kim, Hui Taek ^a   Kwon, Chae Hwa ^a   Park, Ji Yeon ^a   Kim, Yong Keun ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Apoptosis; Caspase; MAPK; Mitochondrial membrane potential; Osteoblasts; Troglitazone

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 CHLORO 5 NITROBENZANILIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ANTIOXIDANT; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; REACTIVE OXYGEN METABOLITE; TROGLITAZONE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DOWN REGULATION; ENZYME INHIBITION; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL;

3T3 CELLS; ANILIDES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BUTADIENES; CASPASE 3; CELL SURVIVAL; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FLOW CYTOMETRY; HYPOGLYCEMIC AGENTS; IMIDAZOLES; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; OSTEOBLASTS; PPAR GAMMA; PYRIDINES; REACTIVE OXYGEN SPECIES; THIAZOLIDINEDIONES;

EID: 34047143137     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2007.02.005     Document Type: Article

References (48)

1. Akasaki Y., Liu G., Matundan H.H., Ng H., Yuan X., Zeng Z., Black K.L., and Yu J.S. A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J. Biol. Chem. 281 (2006) 6165-6174
2. Aoun P., Watson D.G., and Simpkins J.W. Neuroprotective effects of PPARgamma agonists against oxidative insults in HT-22 cells. Eur. J. Pharmacol. 472 (2003) 65-71
3. Atarod E.B., and Kehrer J.P. Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines. Free Radic. Biol. Med. 37 (2004) 36-47
4. Bruemmer D., Yin F., Liu J., Berger J.P., Sakai T., Blaschke F., Fleck E., Van Herle A.J., Forman B.M., and Law R.E. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ. Res. 93 (2003) e38-e47
5. Chen F., Wang M., O'Connor J.P., He M., Tripathi T., and Harrison L.E. Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. J. Cell. Biochem. 90 (2003) 732-744
6. Clay C.E., Namen A.M., Fonteh A.N., Atsumi G., High K.P., and Chilton F.H. 15-deoxy-delta(12,14)PGJ(2) induces diverse biological responses via PPARgamma activation in cancer cells. Prostagland. Other Lipid Mediat. 62 (2000) 23-32
7. Cobb M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 71 (1999) 479-500
8. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 326 (1997) 1-16
9. Denizot F., and Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Meth. 89 (1986) 271-277
10. Fujiwara T., and Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci. 67 (2000) 2405-2416
11. Gardner O.S., Dewar B.J., Earp H.S., Samet J.M., and Graves L.M. Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J. Biol. Chem. 278 (2003) 46261-46269
12. Grommes C., Landreth G.E., and Heneka M.T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5 (2004) 419-429
13. Haraguchi M., Torii S., Matsuzawa S., Xie Z., Kitada S., Krajewski S., Yoshida H., Mak T.W., and Reed J.C. Apoptotic protease activating factor 1 (Apaf-1)-independent cell death suppression by Bcl-2. J. Exp. Med. 191 (2000) 1709-1720
14. Kim E.J., Park K.S., Chung S.Y., Sheen Y.Y., Moon D.C., Song Y.S., Kim K.S., Song S., Yun Y.P., Lee M.K., Oh K.W., Yoon do Y., and Hong J.T. Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. J. Pharmacol. Exp. Ther. 307 (2003) 505-517
15. Kim S.H., Yoo C.I., Kim H.T., Park J.Y., Kwon C.H., and Kim Y.K. Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells. Toxicol. Appl. Pharmacol. 215 (2006) 198-207
16. Kondo M., Oya-Ito T., Kumagai T., Osawa T., and Uchida K. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J. Biol. Chem. 276 (2001) 12076-12083
17. Kramer D.K., Al-Khalili L., Perrini S., Skogsberg J., Wretenberg P., Kannisto K., Wallberg-Henriksson H., Ehrenborg E., Zierath J.R., and Krook A. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor {delta}. Diabetes 54 (2005) 1157-1163
18. Kroemer G., Dallaporta B., and Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu. Rev. Physiol. 60 (1998) 619-642
19. Leesnitzer L.M., Parks D.J., Bledsoe R.K., Cobb J.E., Collins J.L., Consler T.G., Davis R.G., Hull-Ryde E.A., Lenhard J.M., Patel L., Plunket K.D., Shenk J.L., Stimmel J.B., Therapontos C., Willson T.M., and Blanchard S.G. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41 (2002) 6640-6650
20. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
21. Lennon A.M., Ramauge M., Dessouroux A., and Pierre M. MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. J. Biol. Chem. 277 (2002) 29681-29685
22. Li L., Tao J., Davaille J., Feral C., Mallat A., Rieusset J., Vidal H., and Lotersztajn S. 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J. Biol. Chem. 276 (2001) 38152-38158
23. Li M., Lee T.W., Mok T.S., Warner T.D., Yim A.P., and Chen G.G. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J. Cell. Biochem. 96 (2005) 760-774
24. Li M., Lee T.W., Yim A.P., Mok T.S., and Chen G.G. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells. J. Cell. Physiol. 209 (2006) 428-438
25. Lovekamp-Swan T., and Chaffin C.L. The peroxisome proliferator-activated receptor gamma ligand troglitazone induces apoptosis and p53 in rat granulosa cells. Mol. Cell. Endocrinol. 233 (2005) 15-24
26. Martindale J.L., and Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 192 (2002) 1-15
27. Motomura W., Tanno S., Takahashi N., Nagamine M., Fukuda M., Kohgo Y., and Okumura T. Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 332 (2005) 89-94
28. Murphy G.J., and Holder J.C. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci. 21 (2000) 469-474
29. Narayanan P.K., Hart T., Elcock F., Zhang C., Hahn L., McFarland D., Schwartz L., Morgan D.G., and Bugelski P. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. Cytom. A 52 (2003) 28-35
30. Nikitakis N.G., Siavash H., Hebert C., Reynolds M.A., Hamburger A.W., and Sauk J.J. 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. Br. J. Cancer 87 (2002) 1396-1403
31. Nishijima C., Kimoto K., and Arakawa Y. Survival activity of troglitazone in rat motoneurones. J. Neurochem. 76 (2001) 383-390
32. Pandhare J., Cooper S.K., and Phang J.M. Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms. J. Biol. Chem. 281 (2006) 2044-2052
33. Pastorino J.G., Chen S.T., Tafani M., Snyder J.W., and Farber J.L. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J. Biol. Chem. 273 (1998) 7770-7775
34. Pastorino J.G., Snyder J.W., Serroni A., Hoek J.B., and Farber J.L. Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. J. Biol. Chem. 268 (1993) 13791-13798
35. Perez-Ortiz J.M., Tranque P., Vaquero C.F., Domingo B., Molina F., Calvo S., Jordan J., Cena V., and Llopis J. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J. Biol. Chem. 279 (2004) 8976-8985
36. Piva R., Gianferretti P., Ciucci A., Taulli R., Belardo G., and Santoro M.G. 15-Deoxy-{Delta}12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-{kappa}B activity and down-regulation of antiapoptotic proteins. Blood 105 (2005) 1750-1758
37. Riggs B.L., and Parfitt A.M. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 20 (2005) 177-184
38. Rosen E.D., and Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276 (2001) 37731-37734
39. Shan Z.Z., Masuko-Hongo K., Dai S.M., Nakamura H., Kato T., and Nishioka K. A potential role of 15-deoxy-delta(12,14)-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis. J. Biol. Chem. 279 (2004) 37939-37950
40. Strakova N., Ehrmann J., Bartos J., Malikova J., Dolezel J., and Kolar Z. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma 52 (2005) 126-136
41. Teruel T., Hernandez R., Benito M., and Lorenzo M. Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes. J. Biol. Chem. 278 (2003) 263-269
42. Tsuchiya T., Shimizu H., Shimomura K., and Mori M. Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells. Am. J. Nephrol. 23 (2003) 222-228
43. Ward C., Dransfield I., Murray J., Farrow S.N., Haslett C., and Rossi A.G. Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism. J. Immunol. 168 (2002) 6232-6243
44. Willson T.M., Lambert M.H., and Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70 (2001) 341-367
45. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
46. Yamakawa-Karakida N., Sugita K., Inukai T., Goi K., Nakamura M., Uno K., Sato H., Kagami K., Barker N., and Nakazawa S. Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ. 9 (2002) 513-526
47. Yoshida K., Tanabe K., Fujii D., Oue N., Yasui W., and Toge T. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 23 (2003) 267-273
48. Zander T., Kraus J.A., Grommes C., Schlegel U., Feinstein D., Klockgether T., Landreth G., Koenigsknecht J., and Heneka M.T. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J. Neurochem. 81 (2002) 1052-1060